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nti-heart antibodies have been de- A tected by different immunologic 
methods in the serum of patients with 
various heart diseases, especially that of 
rheumatic origin.1-5 The prevalence of 
these serum antibodies in patients with 
nonrheumatic heart disease has been rela- 
tively 10w.~-* Thus, the adjunctive use of 
iznmunologic methods for the clinical 
detection of heart disease appeared to be 
of limited value unless the sensitivity 
and yield of significant positives could be 
increased. This paper reports further stud- 
ies on anti-heart serum factors which in- 
crease the diagnostic potential of such 
blood tests in patients with heart disease, 
especially m).ocardial infarction. 
Methods and materials 
Samples of serum were taken from pa- 
tients with myocardial infarction. Serum 
from normal people and hospital patients 
lvith various diseases \vas also studied. 
In this study, a patient was considered 
to have a myocardial infarction if the 
electrocardiogram (ECG) showed typical 
changes of transmural infarction or if 
atypical changes were accompanied by 
an elevated serum glutamic oxaloacetic 
transaminase activity (SGOT). The anti- 
gens used in this study were prepared from 
human tissues which were histologicall> 
normal, obtained at postmortem I\-ithin 
6 hours of death from individuals I\-ith 
tJ,pe 0 tjlood, whose clinical course and 
postmortem examination revealed no evi- 
dence of cancer or infection. A moditication 
of the Boyden tanned red blood cell henlag- 
glutination tests was employed to detwt 
anti-organ antibodies in the serum.!’ T!.iw 
0 human erythrocytes were coat.~d \\.ith 
a 1 :looo ~ralll-VOlUIlle COnCen~IYl~~tJll Of 
tissue antigen extract prepared in the 
following way: One gram of freshly. wasl~ed 
tissue was homogenized in 10 ml. of phos- 
phate-buffered normal saline, pH 6.4, for 
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2 minutes at 4’C., using a Virtis homo- 
genizer. The homogenate was allowed to 
extract for 15 minutes at 4’C. and then 
was centrifuged at 1,SOO r.p.m. for 10 
minutes. The supernatant lvas diluted 
1:lOO with the buffered saline. All extracts 
lvere prepared fresh and used within 90 
minutes. All runs contained the following 
controls: a positive serum of known titer, 
a negative serum, and a typical checker- 
board of cross reactions between all re- 
actants. If the test serum did not hemag- 
glutinate heart-extract-sensitized tanned 
erythrocytes, then a test for the presence 
of inhibitors was performed by adding a 
constant volume of anti-heart positive 
serum to each tube of the negative test 
serum and the negative control serum 
series so that the tubes of the negative 
control series became positive. The tubes 
were shaken, the cells resuspended, and 
the test ~vas read after 2 hours. If inhibitors 
were present, the tubes containing higher 
concentrations of test serum suppressed 
hemagglutmation, whereas those contain- 
ing lower concentrations did not. The 
titer of the inhibitor was taken as the 
dilution of the last tube in which hemag- 
glutination was suppressed. Some of the 
sera which gave negative results on direct 
hemagglutination were incubated xvith 
positive anti-heart antiserum or with 
heart-extract-sensitized tanned red blood 
cells prior to repeating the test, in order 
to ascertain whether the site of action of 
the inhibition was with antibodies in the 
antiserum or with antigen on the erythro- 
cytes or at both of these locations. Cross 
reactions with other organ extracts were 
studied with hemagglutination and hemag- 
glutination-inhibition methods. 
Results 
Table I presents the results of direct 
and inhibition hemagglutination tests per- 
formed on the serum of normal people 
and on that of patients with myocardial 
infarction. The infarctions had occurred 
9 days to 15 years earlier. The difference 
in the prevalence of positive hemaggluti- 
nation tests between the group with myo- 
cardial infarction and the normal group 
is significant for both direct (p < O.OSj 
and inhibition (0.025 > p > 0.01) testing. 
Table II presents the data on serum 
hemagglutination tests in patients with 
various diseases. Direct hemagglutination 
occurred in cases of heart disease. Positive 
inhibition reactions occurred in patients 
lvith diseases which usually involve 1)lood 
vessels, e.g., lupus erythematosus, syphilitic 
aortitis, and pulmonary embolism. 
TalJe III presents the results of tests 
for the presence of anti-heart hemaggluti- 
nation inhibitors in sera which were ncga- 
tive for anti-heart antibodies by direct 
hemagglutination. When the test sera 
were preincubated with the antigen-coated 
cells, the results were identical to those 
obtained Lvith the initial inhibition test. 
Inhibition occurred with the serum from 
one patient in the myocardial infarction 
group (No. S), and with that from the 
three persons in the normal group (Nos. 
8, 9, and lo), regardless of whether prc- 
incubation was with antigen-coated cells 
or anti-heart antiserum. All four had 
titers of 1:128 or 1:256. Serum from Pa- 
tients Nos. 2, 4, and 7 inhibited only after 
incubation with anti-heart antiserum. 
Table IV lists the hemagglutination 
test results with the intervals since the 
oldest and most recent infarctions. 
Table I. Results of serlhm antGhlbman heart hemag&tination tests in normal people and futients 
with myocardial infarction* 
I 
Patient groups 
~ Direct hemagglutination Inhibition hemagglutination 
---------- ~.. 
I 
Negative Total Positive Negative ’ Total 
Myocardial infarction 8 15 23 7 6 13 
Normal 3 47 50 3 20 23 
*Numbers indicate the number of people in each category. 
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~ -,---T- ~ 
Negative , Total i Positive Ncga t ive I To&l 
2 3 .5 1 2 3 
Miscellaneous 
Rheumatoid arthritis 1 
Rheumatic heart disease 4 
Lupus erythematosus (SI,E) 0 
Syphilitic aortitis 0 
Pulmonary embolism 0 
Pleurisy 0 
Electrical shock 0 











0 1 1 
1 0 1 
1 0 1 
1 0 1 
1 0 1 
0 1 1 
0 1 1 
0 1 1 
*Numbers indicate the number of people in eac~~ cakgory. 
I’uble III. Resz1It.s of anti-heart hemaggl&ination inhibition tests 
F’ye-incubation with 
---~~~- ~~.- 
Direct Initial inhibition 
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Discussion 
The sera of 29 per cent of the patients 
with myocardial infarction gave positive 
anti-heart hemagglutination tests, as com- 
pared to 6 per cent in the normal group 
(p < 0.005). This low frequency of positive 
tests in normal individuals has been re- 
port,yj.~,5z~~,ll The prevalence of positive 
tests in the group with myocardial infarc- 
tion compares favorably with the experi- 
ence of others employing similar meth- 
ods5f’jJ1 and precipitin procedures12 but 
is less than that observed with immuno- 
fluorescent techniques.lS Four of 5 patients 
with inactive rheumatic heart disease 
had positive anti-heart hemagglutination 
tests. This is similar to the frequency (92 
per cent) reported by Zablocki.S Hess 
and Fink6 found 63 per cent positive re- 
sults in patients with active rheumatic 
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Tuble 11J. Intervals between anti-heart hemagglutination tests and myocardial iplufarction 
Interval since myocardial infarction 
First Last ok only 
I 
Direct hemagglutinatioz Inhibition hemagglutination 
(reciprocal of titer) (reriprocal of iiter) 
10 yr. ? 2% 
14 days 32 
1.5 yl-. 22 1~0, 64 
18 days -l 
9 days m 
6 1110. 4 
4 y. 21 days 128 
3 y-. ? 128 
8 mo. 6 days Negative 128 
? 8 yr. Negative 128 
? 7 days Yegative 1,028 
10 yr. 47 days Kegative 0 
11 days Negative 0 
2 mo. Kegative 128 
45 days Yegative 0 
? Negative 0 
? = Exact ds.te of infarction not known. 
heart disease, but only 16 per cent in pa- 
tients in whom the disease was in the in- 
active stage. Occasional reports of tests 
of the serum of individuals with “cardio- 
myopathy” have been included in papers 
on anti-heart serum factors1 Two of 5 
such patients in this study had anti-heart 
antibodies. 
These findings indicate a firm relation- 
ship between anti-heart serum hemag- 
glutinins and structural heart disease, 
wit6 the former being more likely an effect 
than a cause of the heart disease, except, 
perhaps, in the case of acute rheumatic 
fever.7,14,1G There appears to be no clear 
relationship to a single pathologic change 
in the heart, since anti-heart hemaggluti- 
nation reactions occurred in patients whose 
hearts were involved by acute or chronic 
inflammatory, degenerative, or necrotic 
processes, a situation also reported by 
others.Tb1hJ7 It would seem that these pa- 
tignts are responding to a number of heart 
antigens by forming immunoglobulins that 
range from relatively nonspecific to cross 
reacting or highly speciiic.11J5~1*-z1 Serum 
from normal individuals and from patients 
with vascular or other cardiac diseases 
did not often give the positive anti-heart 
hemagglutination test results commonly 
encountered with serum from patients 
with myocardial infarction, rheumatic heart 
disease, or cardiomyopathy. There was 
no association between the presence or 
titer of anti-heart hemagglutinins and 
the number of infarctions or the interval 
since infarction. In rheumatic heart dis- 
ease, cross-reacting antistreptococcal wall 
antibodies, as well as anti-heart factors, 
could be responsible for the positive tests 
observed. Anti-heart serum factors have 
been reported in lupus erythematosus and 
q~philis,~~~~~~~ but were not detected in 
this study. The serum in one case of in- 
active rheutnatoid arthritis produced hem- 
agglutination at a titer of 1:16. 
Anti-heart hemagglutination inhibitors 
were more frequently encountered in the 
serum of patients with myocardial infarc- 
tion than in that of normal subjects (Table 
I), but were observed in the serum of 
patients with cardiomyopathy, lupus ery- 
thematosus, syphilitic aortitis, pulmonary 
embolism, and pleurisy. Except for the 
case of pleurisy, they were not found in 
the absence of cardiac or vascular disease 
(Table II). 
Three types of anti-heart hemaggluti- 
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nation inhibition are observed: at the 
imtigen site, at the antiserum site, or at 
ljoth sites. Except for the serum of one 
patient with myocardial infarction, dual 
inhillition occurred only in the serum 
from 3 normal subjects. Anti-heart in- 
hibitors are relatively uncommon in nor- 
mal individuals, in contrast to patients 
with myocardial infarction. They are also 
observed in persons with other diseases 
in lj,hich there is cardiac or vascular in- 
volvement (cardiom>-opathy, lupus erythe- 
matosus, syphilitic aortitis, and pulmonary 
embolisnY1. Inhibition was not present in 
the one case of inactive rheumatic heart 
disease studied. 
It seems, therefore, that chronic inflam- 
matory mechanisms involving the cardio- 
vascular system are frequently associated 
with solitary anti-heart hemagglutination 
inhibitors acting at either the antigen or 
antisermll site. Sera exhibiting dual in- 
hibition are less specific and were found 
in normal subjects and in one patient with 
in>-ocardial infarction. Inhibitors in serum 
were observed as early as 6 days and as 
late as 2 months after myocardial infarc- 
tion (TalAe I\-). Titers ranged from 1:128 
to 1:1028 and were present in persons with 
one infarction as l\-ell as in those with 
several infarctions. There were no apparent 
correlations between the titers of inhibi- 
tors, the time since infarction, or the 
numl)er of infarctions. 
The immunologic signilicance of these 
findings is difficult to assess. The inhibition 
observed against the heart antigens could 
lje explained by the presence of incomplete 
anti-heart antibodies or cross-reacting im- 
munoglobulins, but is more likely due to 
anti-heart immunoglobulins of the C; or 
7s tl.pe.gz-?4 Inhibition occurring at the 
antiserum site could be the result of circu- 
lating heart antigens, other tissue antigens 
possessing simi!ar determinants,YA or anti- 
~~~~ii~~i~iglol~~~li~is (e.g., seruni normal ag- 
glutinators, rheumatoid agglutinators, 
“Alilgrom factors,” etc.z5). The nonspecific 
dud inhibition could be explained by the 
presence of several of the latter factors, 
especialI>. those immunoglobulins acting 
against antigen-antibody complexes, gam- 
nlaglobulin aggregates, or proteins with 
semi-available determinants. Other inves- 
tigators have presented evidence to sug- 
gest that damaged tissue itself releases 
nonspecific immunoglobulins which persist 
for weeks.z6,z7 
Although the reason for the presence of 
the anti-heart inhibitors is not apparent, 
they are found in the serum of patients 
with heart disease and may prove to have 
diagnostic usefulness. 
Summary 
Serum anti-heart hemagglutinins oc- 
curred in 29 per cent of patients with 
myocardial infarction, as compared to 6 
per cent of normal control subjects, had 
a high prevalence in patients with rheu- 
matic heart disease, occurred in 2 of 5 with 
a cardiomyopathv, and had a very low 
frequencv in inckviduals who had non- 
cardiac diseases with or without a vascular 
component. 
Serum inhibitors of anti-heart hemag- 
glutinations were found in one half of the 
patients jvith myocardial infarction and 
in those having diseases with vascular 
involvement, e.g., lupus erythematosus, 
pulmonary embolism, and syphilitic aorti- 
tis. The inhibitors found associated with 
cardiovascular diseases inhibit at either 
the antigen or antiserum site during the 
hemagglutination test, whereas the normal 
sera which displa>r inhibition do so at 
both sites, suggesting a lack of anti-heart 
specificity. From these data it appears 
that, jvith the sequential use of both the 
anti-heart hemagglutination technique and 
the inhitlition test, positive results can be 
obtained in over one half of the patients 
with mvocardial infarction. 
As diagnostic adjuncts, these tests still 
offer only limited assistance in the clinical 
detection of cardiovascular diseases. A 
positive anti-heart hemagglutination in- 
hibition test alone appears to be relatecl to 
less specific vascular damage. 
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